Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
暂无分享,去创建一个
F. Marincola | S. Rosenberg | P. Hwu | Y. Zhai | S. Topalian | D. White | D. Schwartzentruber | N. Restifo | C. Seipp | J. Einhorn | J. Yang | S A Rosenberg | S L Topalian | F M Marincola | J C Yang | N P Restifo | D J Schwartzentruber | Y Zhai | P Hwu | C A Seipp | J H Einhorn | B Roberts | D E White | B. Roberts | J. C. Yang | Steven A. Rosenberg | Patrick Hwu | Bruce L. Roberts | F. M. Marincola | F. Marincola | Yifan Zhai | Jan Einhorn | Donald E. White
[1] Joseph Zabner,et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis , 1993, Cell.
[2] H. Ertl,et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.
[3] H. Ertl,et al. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.
[4] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[5] S. Rosenberg,et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.
[6] S. Rosenberg,et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.
[7] J. Renauld,et al. Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes , 1995, Immunological reviews.
[8] J. Renauld,et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.
[9] J. Cormier,et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.
[10] S. Rosenberg,et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. , 1996, Journal of immunology.
[11] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[12] J. Wilson,et al. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. , 1994, Circulation.
[13] B. A. French,et al. The Advent of Adenovirus Gene Therapy for Cardiovascular Disease , 1993, Circulation.
[14] S. Rosenberg,et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Zinkernagel,et al. Induction of Protective Cytotoxic T Cell Responses in the Presence of High Titers of Virus-neutralizing Antibodies: Implications for Passive and Active Immunization , 1998, The Journal of experimental medicine.
[16] R. Gregory,et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway , 1997, Gene Therapy.
[17] P. Chanda,et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. , 1993, AIDS research and human retroviruses.
[18] F. Graham,et al. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. , 1991, Journal of acquired immune deficiency syndromes.
[19] R. Johnson,et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. , 1996, Gene therapy.
[20] F. H. Top. Control of adenovirus acute respiratory disease in U.S. Army trainees. , 1975, The Yale journal of biology and medicine.
[21] R. Crystal,et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. , 1997, Human gene therapy.
[22] R. Ricciardi,et al. Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. , 1997, Journal of immunology.
[23] E. Nabel,et al. Gene therapy for cardiovascular disease. , 1995, Circulation.
[24] S. Rosenberg,et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.
[25] S. Rosenberg. Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.
[26] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[27] J. Gall,et al. Circumventing the immune response to adenovirus-mediated gene therapy. , 1996, Gene therapy.
[28] M. Kay,et al. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[29] A. Takeshita,et al. Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[30] J. Imler. Adenovirus vectors as recombinant viral vaccines. , 1995, Vaccine.
[31] A. Sette,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.
[32] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[33] S. Rosenberg,et al. The development of new cancer therapies based on the molecular identification of cancer regression antigens. , 1995, The cancer journal from Scientific American.
[34] A. Ribas,et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. , 1997, Cancer research.
[35] M. Salgaller,et al. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[36] M. Levine,et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. , 1992, Vaccine.
[37] G. Contreras,et al. Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines. , 1986, Canadian journal of public health = Revue canadienne de sante publique.
[38] D. Dichek,et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. , 1997, The Journal of clinical investigation.
[39] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Welsh,et al. Safety and efficacy of repetitive adenovirus–mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats , 1994, Nature Genetics.
[41] J. Wilson,et al. Gene therapy: adenovirus vectors. , 1993, Current opinion in genetics & development.
[42] R. Crystal,et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.
[43] F. Marincola,et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.
[44] B. Trapnell,et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. , 1994, Gene therapy.
[45] M. Perricaudet,et al. Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. , 1993, The Journal of clinical investigation.
[46] M. Welsh,et al. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. , 1993, Human gene therapy.
[47] S. Rosenberg. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. , 1996, Journal of the National Cancer Institute.